Latest Articles

This article dwells upon the challenges presented by prevailing data visualization solutions for drug discovery and covers how enablers such as AI and VR have transformed the drug discovery data visualization market. It touches upon examples of existing solutions, new players and upcoming industry partnerships.

A story of the Elvesys Innovation Unit, a research institute in France designed to unite entrepreneurs involved in microfluidics research.

Male contraceptive methods account for just 25% of all contraceptive use worldwide. We recently spoke with Christina Wang, MD and Stephanie Page MD, PhD – involved in the development of two male oral contraceptive drugs. They discuss recent clinical study results, explain how the drugs work, and highlight the various alternative drug delivery methods they are currently investigating.

The final instalment of The Evolution of Proteomics series features an interview with Professor John Yates from the Department of Molecular Medicine at Scripps Research. The Yates laboratory is focused on developing strategies and tools in proteomics to answer basic biological questions.

AI is rapidly being adopted in the pharmaceutical industry. Nonetheless, much pharmaceutical development data is limited, resulting in restricted amounts of usable data. Sparse data AI – the application of AI to restricted amounts of data – is opening up novel avenues for enhanced drug development. In this article, Nanoform’s Jukka Corander looks at how sparse data can help pharma industry AI gain greater transparency and lead to more life-changing medicines reaching the market.

In this instalment of The Evolution of Proteomics, we speak with Dr Alexander Makarov, Director of Research in Life Sciences Mass Spectrometry (MS) at Thermo Scientific, and world-renowned inventor of the Orbitrap mass analyzer technology.

In partnership with researchers from Raytheon and other universities, Eric Young, assistant professor of chemical engineering at Worcester Polytechnic Institute, is creating a method for using DNA signatures to identify genetically engineered organisms in the wild. We spoke with Young to learn more about why such tools are needed and the process of their development.

The development of technical grade pesticides has enabled farmers to reduce crop losses, but it is important to recognize that pesticides are toxic by design, and so it is also important to have sufficient technology to monitor their presence in our produce and on our farmland. We take a look at some alternative techniques that are being applied to this issue.

Structural biology has recently observed the marrying of two remarkably complimentary techniques for the study of protein structure and interaction: cross-linking mass spectrometry (XL-MS) and the Nobel prize winning cryogenic electron microscopy (cryo-EM).

In this instalment of The Evolution of Proteomics, Gary Kruppa, Vice President of Proteomics, Bruker Daltonics Inc., discusses the recent technological advances that are driving MS-based plasma proteomics for biomarker discovery and beyond.